Table 5 presents the number of patients who, at time periods 5, 7, or 9, switched or discontinued AD treatment and discontinued AD treatment because they were symptom-free, because of ineffective treatment or because treatment resulted in too many side effects across CYP enzymes and metabolizer status. This evidence concerns the gene PPIG and Alzheimer disease.